Immunotherapy Combinations for Non-Small Cell Lung Cancer
(Morpheus Lung Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non-small cell lung cancer (NSCLC).Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of participants with tumor PD-L1 expression who have received no prior systemic therapy for metastatic NSCLC, and Cohort 2 will consist of participants who experienced disease progression during or following treatment with a platinum-containing regimen and a PD-L1/PD-1 checkpoint inhibitor, given in combination as one line of therapy or as two separate lines of therapy, regardless of PD-L1 expression. In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). Participants who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen (Stage 2).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is the combination of immunotherapy and chemotherapy safe for treating non-small cell lung cancer?
Research shows that combining immunotherapy drugs like pembrolizumab and atezolizumab with chemotherapy drugs such as pemetrexed and carboplatin is generally safe for treating non-small cell lung cancer, though some patients may experience side effects. These side effects can vary in severity, and taking supplements like folic acid and vitamin B12 can help improve safety without reducing effectiveness.12345
What makes the drug combination of Atezolizumab, Carboplatin, and Pemetrexed unique for treating non-small cell lung cancer?
This drug combination is unique because it combines immunotherapy (Atezolizumab) with chemotherapy (Carboplatin and Pemetrexed), offering an effective first-line treatment option for non-small cell lung cancer regardless of PD-L1 expression, which is a protein that can affect how well the immune system can attack cancer cells.23678
What data supports the effectiveness of the drug combination Atezolizumab, Carboplatin, and Pemetrexed for treating non-small cell lung cancer?
Who Is on the Research Team?
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Are You a Good Fit for This Trial?
This trial is for adults with metastatic non-small cell lung cancer. Cohort 1 includes those who haven't had systemic therapy and have high PD-L1 in tumors. Cohort 2 has patients whose disease progressed after platinum-based and PD-L1/PD-1 inhibitor treatments. Participants must be able to perform daily activities with minimal assistance, have a life expectancy of at least 3 months, measurable disease, proper organ function, and agree to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Stage 1
Participants receive various immunotherapy-based treatment combinations until unacceptable toxicity or loss of clinical benefit
Treatment Stage 2
Participants who experience disease progression or loss of clinical benefit in Stage 1 may continue treatment with a different regimen
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Atezolizumab
- Carboplatin
- Pemetrexed
- Radiation
Atezolizumab is already approved in United States, European Union for the following indications:
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University